mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Affordability is key to providing accessible healthcare for Bharat.
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
Science communication brings behavioural changes
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
The session took place in the presence of Union Ministers Hardeep Singh Puri and Gen V K Singh along with Anil Agarwal, Rajya Sabha Member of Parliament
Urges everyone to follow COVID Appropriate Behaviour and curb any misinformation
To enable company to be future-ready by tapping potential in CDMO space
Subscribe To Our Newsletter & Stay Updated
